Skip to main content

Resistance to Immunotoxins in Cancer Therapy

  • Book
  • © 2015

Overview

  • Identifies the mechanisms of resistance in immunotoxin-based therapies for cancer
  • Explores available measures to overcome and prevent resistance in immunotoxin drugs
  • Discusses an array of immune responses in cancer that impact therapeutic strategies

Part of the book series: Resistance to Targeted Anti-Cancer Therapeutics (RTACT, volume 6)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (9 chapters)

Keywords

About this book

This book will be a guide to understanding resistance against targeted therapeutic approaches for cancer using immunotoxins. It contains a detailed review of the history and development of targeted therapy. As well, it includes an in-depth description of the molecular and cellular mechanisms involved in cancer resistance and several novel methods to overcome resistance. Each chapter discusses different aspects of resistance and covers all the factors that may contribute to resistance in cancer cells. Finally, this volume highlights the recent findings and advances associated with tackling cancer resistance.

Editors and Affiliations

  • Department of Biotechnology, Indian Institute of Technology Madras, Chennai, India

    Rama Shanker Verma

  • Department of Microbiology, Immunology,, University of California of Los Angeles, Los Angeles, USA

    Benjamin Bonavida

About the editors

Rama Shanker Verma, Ph.D., is Professor, Department of Biotechnology, the Indian Institute of Technology. Professor Verma specializes in the development of novel immunotoxins for cancer therapies. He has published 76 scientific articles, five book chapters, and several conference abstracts. He is an Elected Fellow, the Association of Microbiologists of India an Elected Fellow, the Society for Applied Biotechnology. He received the award for Excellence in Medical Biotechnology from the Society for Applied Biotechnology.

Bibliographic Information

Publish with us